Header Logo
Investor Relations

Our Pipeline of Therapeutic Candidates

Development Timeline

Product

Discovery

Preclinical

Phase I

Phase II

Phase III

CB – 24

CB – 4

CB – 6

CB – 25

Cancer Detection

  • 60%60%
  • 38%38%
  • 34%34%
  • 29%29%
  • 25%25%

CB-24 CROTOXIN

  • Nicotinic antagonist active against solid tumors.
  • Clinical response in 43% of patients treated in a broad spectrum of cancers including lung, breast, prostate, squamous cell carcinoma, ovarian and cervical cancer.
  • Two-part Phase I intra-patient dose escalation trial completed in patients with advanced solid tumors: low toxicity, analgesic effect, trend to clinical efficacy.
  • Phase I/II new study under preparation.
CLINICAL

CB-4 CROTAMINE

  • Protein kinase inhibitor.
  • Cell penetrating peptide.
  • Inhibits tumor growth in vitro and in vivo with minimal toxicity to normal tissues.
  • Shown active against melanoma (in vivo); cell lines of breast, pancreatic and prostate cancer.
  • Potential gene therapy application.
  • Orally bioavailable.
PRECLINICAL

CB-6 CARDIOTOXIN

  • Protein kinase C inhibitor.
  • Blocks spread of primary tumors.
  • Candidate for adjunct treatment in cancer therapy to enhance efficacy.
  • Orally bioavailable.
PRECLINICAL

CB-25 CROTALIN

(CB-24 + CB-4 combination)

  • Broad spectrum antitumor activity.
  • Minimal side effects.
  • Strong activity in brain, melanoma and mast cell tumors.
  • Aimed at veterinary application.
PRECLINICAL

Cancer Detection

TEST

  • First-line early detection of malignant tumors in urine samples.
  • Detecting a broad spectrum of tumors.
  • High sensitivity.
  • Easy to use.
  • Non-invasive.
PRECLINICAL